Intracellular Th (ITCI)

Name: Intracellular Th (ITCI) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Intracellular Th (ITCI)

Stock Card

$131.87

$0.00 (0.00%)

As on 02-Apr-2025 09:30EDT

Market cap

$14,047 Mln

Revenue (TTM)

$681 Mln

P/E Ratio

P/B Ratio

12.2

Div. Yield

0 %

Intracellular Th (ITCI) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 131.87 High: 131.87

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.1 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-37.1
Debt to Equity

0
Book Value

$11.1
EPS

$-0.7
Face value

--
Shares outstanding

106,522,000

10 Years Aggregate

CFO

$-1,426.99 Mln

EBITDA

$-1,603.63 Mln

Net Profit

$-1,559.60 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Intracellular Th (ITCI)	57.9	2.9	57.9	93.2	28.1	55.6	18.5
BSE Sensex^*	-9.1	1.1	1.2	-4.8	5.8	6.6	10.7
S&P Midcap 400^#	14.3	1.1	3.1	17.9	14.0	7.1	9.4

As on 02-Apr-2025 | *As on 27-Aug-2026 | #As on 27-Aug-2026

Company	2024	2023	2022	2021	2020	2019	2018
Intracellular Th (ITCI)	16.5	35.3	1.1	64.6	-7.3	201.2	-21.2
S&P Midcap 400	12.1	14.4	-14.5	23.2	11.8	24.1	-12.4
BSE Sensex	8.1	18.7	4.4	22.0	15.8	14.4	5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Intracellular Th (ITCI)

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA... for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine. Read more

Co-Founder, Chairman & CEO

Dr. Sharon Mates Ph.D.
Co-Founder, Chairman & CEO

Dr. Sharon Mates Ph.D.
Headquarters

Bedminster, NJ
Website

https://www.intracellulartherapies.com

FAQs for Intracellular Th (ITCI)

What is the current share price of Intracellular Th (ITCI) Today?

The share price of Intracellular Th (ITCI) is $131.87 (NASDAQ) as of 02-Apr-2025 09:30 EDT. Intracellular Th (ITCI) has given a return of 28.14% in the last 3 years.

What is the current PB & PE ratio of Intracellular Th (ITCI)?

Since, TTM earnings of Intracellular Th (ITCI) is negative, P/E ratio is not available.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2024	-115.34	7.50
2023	-49.37	11.66
2022	-19.57	7.64
2021	-15.01	10.20
2020	-11.25	3.89

What is the 52 Week High and Low of Intracellular Th (ITCI)?

The 52-week high and low of Intracellular Th (ITCI) are Rs -- and Rs -- as of 28-Aug-2026.

What is the market cap of Intracellular Th (ITCI)?

Intracellular Th (ITCI) has a market capitalisation of $ 14,047 Mln as on 02-Apr-2025. As per SEBI classification, it is a Mid Cap company.

Should I invest in Intracellular Th (ITCI)?

Before investing in Intracellular Th (ITCI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.